U.S. News Room
Thu Aug 27 00:00:00 GMT-05:00 2026
NEW
DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
Download
Wed Aug 26 00:00:00 GMT-05:00 2026
NEW
TROPION-Urothelial04 Phase 3 Trial of Datroway Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
Download
Mon Aug 24 00:00:00 GMT-05:00 2026
NEW
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
Download
Mon Aug 17 00:00:00 GMT-05:00 2026
NEW
Enhertu Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Download
Thu May 28 00:00:00 GMT-05:00 2026
Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO
Download
Fri May 22 00:00:00 GMT-05:00 2026
Datroway Approved in the US as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Download
Fri May 15 00:00:00 GMT-05:00 2026
Enhertu Approved in the US for Two New Indications for Patients with HER2 Positive Early Breast Cancer
Download
Mon May 11 00:00:00 GMT-05:00 2026
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
Download
Mon Apr 13 00:00:00 GMT-05:00 2026
Ifinatamab Deruxtecan Granted Priority Review in the US for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Download
Mon Mar 09 00:00:00 GMT-05:00 2026
ENHERTU Granted Priority Review in the US as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Download